ABSTRACT: A versatile method for orchestrating the formation of side chain-to-tail cyclic peptides from ribosomally derived polypeptide precursors is reported. Upon ribosomal incorporation into inteincontaining precursor proteins, designer unnatural amino acids bearing side chain 1,3-or 1,2-aminothiol functionalities are able to promote the cyclization of a downstream target peptide sequence via a C-terminal ligation/ring contraction mechanism. Using this approach, peptide macrocycles of variable size and composition could be generated in a pH-triggered manner in vitro or directly in living bacterial cells. This methodology furnishes a new platform for the creation and screening of genetically encoded libraries of conformationally constrained peptides. This strategy was applied to identify and isolate a low-micromolar streptavidin binder (K D = 1.1 μM) from a library of cyclic peptides produced in Escherichia coli, thereby illustrating its potential toward aiding the discovery of functional peptide macrocycles.
M acrocyclic peptides occupy a most relevant region of the chemical space and have attracted increasing attention as molecular scaffolds for addressing challenging pharmacological targets.
1,2 Important benefits arising from the cyclization of peptide sequences include preorganization into a bioactive conformation and reduced entropic costs upon complex formation, which can result in enhanced binding selectivity and affinity, respectively, toward a target biomolecule.
3−10 In addition, macrocyclization has proven to be beneficial toward improving the proteolytic stability 11−13 and cell penetration ability 14−16 of peptide-based molecules. These advantageous features are well-reflected by the widespread occurrence of ring topologies among natural biologically active peptides, such as those produced by nonribosomal peptide synthetases 17, 18 (e.g., cyclosporin, polymyxin) or those belonging to the class of ribosomally synthesized and post-translationally modified peptides (RiPPs) 19 (e.g., lanthipeptides, 20 cyclotides, 21 cyanobactins 22 ). Because of the attractive properties of macrocyclic peptides, the development of methods for the preparation of this class of compounds has attracted significant interest. 23−27 Among these, strategies that rely on the cyclization of genetically encoded peptide sequences offer several advantageous features, which include the opportunity to create and evaluate large combinatorial libraries of these molecules by combining genetic randomization with high-throughput display/screening platforms. 24−26 For example, biopanning of phage displayed peptide libraries cyclized via disulfide bridges 28−32 or exogenous cross-linking agents 33−35 has enabled the discovery of potent inhibitors of enzymes and proteins. Coupling in vitro translation methods with mRNA display, other groups have successfully isolated potent macrocyclic peptide inhibitors for a variety of other therapeutically relevant protein targets. 36−41 Despite this progress, there are currently only a few methods that enable the production of macrocyclic peptides of arbitrary sequence within a cell, thereby providing the capability of coupling library production with a selection system or phenotypic screen. 42−48 In this regard, a viable method is the so-called split-intein-mediated circular ligation of peptides and proteins (SICLOPPS) introduced by Benkovic and coworkers, 49 which enables the intracellular formation of headto-tail cyclic peptides by exploiting the trans splicing reactivity of the natural split intein DnaE. More recently, a strategy useful for the generation in vitro and in vivo of macrocylic peptides constrained by an inter side chain thioether bond was reported by our group. 50 While these methods provide a route to obtain head-to-tail or side chain-to-side-chain cyclic peptides, complementary strategies to access alternative peptide macrocycle architectures would be highly desirable. For example, neither of these approaches allows the formation of side chain-to-tail cyclic peptides, a molecular topology that is found in many bioactive peptide natural products (e.g., bacitracin A, polymixin D).
As part of our efforts toward the development of methods for the synthesis of macrocyclic organo−peptide hybrids, 51−54 we recently described the ability of bifunctional oxyamine/1,3-aminothiol aryl reagents to induce the efficient cyclization of polypeptide precursors containing a target peptide sequence flanked by a side chain keto group and a C-terminal intein. 52 Although two possible routes for macrocyclization are available in this system (e.g., side chain → C-end versus C-end → side chain ligation), our studies revealed that this process is largely driven by the intermolecular attack of the 1,3-aminothiol aryl moiety onto the intein-catalyzed thioester bond within the polypeptide precursor. 53 These mechanistic insights suggested to us the possibility of directing the biosynthesis of side chainto-tail macrocyclic peptides through the ribosomal expression of a precursor polypeptide in which an appropriately designed aminothiol-based unnatural amino acid is placed upstream of an intein (Figure 1 ). Given the expected rate enhancement in moving from an intermolecular to an intramolecular setting, we envisioned this construct could undergo a spontaneous posttranslational self-processing reaction through (a) capturing of the transient intein-catalyzed thioester linkage by the side chain thiol functionality followed by (b) irreversible acyl shift to the neighboring amino group to give the desired macrocyclic peptide. Here, we describe the successful implementation of this design strategy and its functionality toward enabling the ribosomal synthesis of macrocyclic peptides both in vitro and in living cells. Furthermore, it is shown how this approach could be successfully applied to evolve and isolate a cyclopeptide with improved binding affinity toward a model target protein (streptavidin).
■ RESULTS AND DISCUSSION
Synthesis of 1,3-Aminothiol Amino Acid, AmmF. In previous work, we recognized the peculiar ability of an o-aminomercaptomethyl-aryl (AMA) group to undergo efficient Cterminal ligation at GyrA intein thioesters under catalyst-free conditions. 53 On the basis of this knowledge, an amino acid incorporating this reactive moiety, 3-amino-4-mercaptomethylphenylalanine (AmmF, Scheme 1A), was designed in order to test its ability to mediate peptide cyclization according to the strategy outlined in Figure 1 . As outlined in Scheme 1A, gramscale synthesis of AmmF was carried out starting from commercially available methyl 3-amino-4-methyl-benzoate, followed by N-Boc protection, benzylic bromination, and benzylic substitution with tritylmercaptan to afford intermediate 3. Lithium aluminum hydride reduction of the methyl ester group in 3 followed by mesylation and substitution of the mesyl group with diethylacetamidomalonate yielded intermediate 5.
Following deprotection, the desired product, AmmF, was obtained in 41% overall yield over eight steps.
Aminoacyl-tRNA Synthetase for Ribosomal Incorporation of AmmF. With AmmF in hand, we sought to identify an orthogonal aminoacyl-tRNA synthetase (AARS)/tRNA pair for the ribosomal incorporation of this unnatural amino acid (UAA) via amberstop codon (TAG) suppression. 55 Interestingly, a number of engineered AARS enzymes have been shown to be polyspecific, that is, capable of charging a cognate tRNA molecule with multiple UAAs while maintaining discriminating selectivity against the natural amino acids. 56, 57 We reasoned that this feature could be exploited to find a suitable AARS for recognition of AmmF. To this end, we generated a panel of six previously reported AARSs derived from Methanocaldococcus jannaschii tyrosyl-tRNA synthetase (MjTyr-RS) in combination with the cognate amber stop codon suppressor tRNA (MjtRNA Tyr CUA ). This panel included MjTyr-RS variants selected for recognition of 3-aminotyrosine (3AmY), 58 paminophenylalanine (pAmF), 59 p-azidophenylalanine (AzF), 60 p-acetylphenylalanine (pAcF), 61 O-propargyltyrosine (OpgY), 62 and O-(2-bromoethyl)-tyrosine (O2beY) 50 ( Figure  2A ).
Among these, 3AmY-RS was considered to be a particularly promising candidate owing to the structural similarity between 3AmY and AmmF. The relative ability of the AARSs to incorporate AmmF in response to a TAG codon was established via a fluorescence assay with a yellow fluorescent protein (YFP) variant containing an amber stop codon at the N-terminus. In this assay, the suppression efficiency and fidelity of each synthetase is measured based on the relative expression levels of the reporter YFP protein in the presence and absence of AmmF, respectively ( Figure 2B) . Gratifyingly, the 3AmY-RS synthetase was found to be capable of incorporating AmmF with good efficiency as compared to that of most of the other AARSs. Interestingly, the AzF-RS synthetase exhibited even better performance in that respect, as judged by the higher fluorescence signal (+15%) measured in the assay. This result is consistent with previous observations by Schultz and coworkers regarding the ability of AzF-RS to recognize various meta, para-disubstituted phenylalanine derivatives, in addition to AzF. 57 Further experiments were then carried out to quantitatively assess the suppression efficiency of AzF-RS with AmmF. For this purpose, YFP(AmmF) and wild-type YFP were expressed under identical conditions and purified by Ni-affinity chromatography. Direct comparison of the expression yield (16 vs 45 mg/L culture, respectively) indicated a suppression efficiency of 36% ( Figure 2C ), a value comparable to that reported for AARSs specifically evolved for the ribosomal incorporation of other UAAs. 57 Figure 1. Overview of the strategy for generating side chain-to-tail macrocyclic peptides via cyclization of ribosomally derived, inteinfused precursor proteins by means of aminothiol unnatural amino acids. Nu refers to the nucleophilic 1,3-or 1,2-aminothiol moiety.
Characterization of AmmF-Containing Precursor
Proteins. Having identified a viable AARS for AmmF incorporation, we tested the ability of this amino acid to promote peptide macrocyclization according to the scheme outlined in Figure 1 . To this end, we investigated a panel of six constructs encompassing target peptide sequences of variable length (4−12 amino acids) framed in between AmmF and the N198A variant of GyrA mini-intein from Myobacterium xenopi 63 (entries 1−6, Table 1 ). These constructs would allow us to probe the formation of peptide macrocycles of varying ring size. In addition, the N-terminal chitin binding domain (CBD) would serve as a large (∼8 kDa) affinity tag to facilitate both the isolation of the products formed in cells and measurement of the extent of intein cleavage via SDS-PAGE densitometry. Accordingly, the precursor proteins were produced in Escherichia coli cells cotransformed with a pET-based plasmid encoding for the precursor protein and a pEVOL 64 -based plasmid for the coexpression of the AzF-RS/tRNA CUA pair for the site-selective incorporation of AmmF.
Contrary to our expectations, only low levels of intein cleavage (20−25%) were observed for all of the constructs under the applied expression conditions (12 h, 27°C), as determined by SDS-PAGE analysis. These values were comparable to those obtained with control constructs in which AmmF was substituted for a non-nucleophilic UAA (= pAcF). Moreover, no traces of the desired macrocyclic compounds were detected after processing the cell lysates with chitin beads.
These results were surprising, given that compounds sharing the o-amino-mercaptomethyl-aryl moiety of AmmF can induce nearly quantitative clevage of GyrA-fusion proteins (80−90%) in less than 10−12 h. 53 To investigate the basis of this unexpected lack of reactivity, the AmmF-containing constructs were isolated in full-length form using the C-terminal His tag and then incubated with thiophenol to cleave the intein and release the N-terminal CBD-containing fragment. MALDI-TOF analysis of these reactions showed the accumulation of a single product corresponding to the linear peptide with an additional mass of +26 Da for each of the constructs ( Figure  S1 ). In contrast, under identical conditions, control proteins containing pAcF instead of AmmF produced a species corresponding to the expected linear peptide with no modifications. These results pointed at a post-translational modification occurring specifically at the level of the unnatural amino acid in the AmmF-containing constructs. The observed mass difference was found to be consistent with the formation of a 2,4-dihydro-benzo[1,3]thiazine adduct ( Figure 3A , species b′) resulting from a condensation/decarboxylation reaction of the AMA moiety in AmmF with pyruvate, an abundant metabolite in E. coli. 65 Importantly, a similar reaction, leading to a thiazolidine adduct, was reported for polypeptides carrying an exposed N-terminal cysteine upon expression in this organism. 66 To confirm the assignment, a model reaction was carried out by incubating a small-molecule surrogate of AmmF, methyl 3-amino-4-(mercaptomethyl)benzoate, with pyruvate under physiological conditions (50 mM KPi, 150 mM NaCl, pH 7.5). LC-MS analysis revealed quantitative conversion of the compound to the pyruvate condensation adduct within a short time ( Figure S2 ). Altogether, these experiments indicated that rapid and quantitative intracellular modification of AmmF by pyruvate impedes the desired in vivo peptide cyclization process. Attempts to minimize this modification by altering the expression conditions 66 failed to result in a detectable increase of the unmodified AmmF-containing protein.
In Vitro Macrocyclization of AmmF-Containing Constructs. These findings prompted us to explore the possibility to execute the desired AmmF-mediated peptide macrocyclization upon chemical unmasking of its modified 1,3-aminothiol functionality. While not directly applicable for intracellular synthesis of cyclic peptides, this approach would provide a means to trigger the formation of peptide macrocycles in a time-controlled manner in vitro. Although deprotection of cysteine-derived thiazolidines has been achieved under rather harsh, protein-denaturing conditions (0.2 M methoxyamine, 6 M guanidinium chloride), 67, 68 we discovered that the AmmF dihydrobenzothiazine adduct can be readily converted to the free 1,3-aminothiol counterpart by simple exposure of the protein to slightly acidic pH, under which conditions the GyrA intein remains functional. Gratifyingly, incubation of the AmmF-containing constructs at pH 5.0 and in the presence of sodium 2-sulfanylethanesulfonate (MESNA) resulted in the formation of small molecular weight products with masses corresponding to the expected CBD-fused peptide macrocycle in each case, as determined by MALDI-TOF MS ( Figure S3 ). Notably, identical results could be achieved in the absence of any thiol catalyst, resulting in the clean formation of the desired macrocyclic lactams as the only product ( Figure 4A ).
Exposure of these macrocyclic products to iodoacetamide resulted in complete conversion to the S-alkylated adduct (+57, Figure S4 ), demonstrating the occurrence of the desired S → N acyl transfer rearrangement (c′ → d′ step, Figure 3A ) to give rise to the hydrolytically stable side chain-to-C-terminus amide linkage. Although the extent of intein cleavage in these reactions was not elevated (15−28%, Figure 4B ), AmmFmediated cyclization was found to be largely independent of the target peptide length, enabling the formation of peptide macrocycles spanning from 4 to 12 amino acid residues with equal efficiency. Suspecting that steric clashes between the CBD and intein protein may disfavor attack of AmmF thiol group onto the downstream thioester ( Figure 3A ), an 8-mer construct in which the CBD was replaced with a smaller Nterminal tail (Met-Gly) was also tested (entry 7, Table 1 ). Incubation of the corresponding protein precursor at pH 5.0 resulted in the formation of the desired peptide macrocycle, whose cyclic structure was further confirmed by MS/MS analysis ( Figure 4C ). Importantly, the construct was determined to undergo 64% intein cleavage (vs 28% for the CBD-fused counterpart), with the macrocycle being the only detectable product, thereby demonstrating the possibility to 
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Articles dramatically increase the yields of these macrocyclization reactions via the use of shorter (or more flexible) N-terminal tails.
Design and Synthesis of 1,2-Aminothiol Unnatural Amino Acid for in Vivo Macrocycle Formation. Having demonstrated the possibility to generate macrocyclic peptides in vitro by means of AmmF, we next sought an alternative aminothiol UAA to enable this process to take place in vivo. To this end, a second phenylalanine derivative was designed, namely, 3-(2-mercapto-ethyl)amino-Phe (MeaF, Figure 1 ), which was expected to exhibit superior performance compared to that of AmmF based on the following arguments. First, the secondary amino group of MeaF was expected to disfavor condensation with pyruvate in cells, thereby preserving the side chain aminothiol functionality required for cyclization. Second, the more acidic and less sterically hindered sulphydryl group in MeaF compared to that in AmmF (i.e., pK a of ∼8.5 69 vs ∼9.5 70 ) would favor nucleophilic attack onto the downstream intein thioester, in particular under the near-neutral conditions of the intracellular milieu. Third, the thiolactone formed during the initial transthiosterification step was envisioned to be less strained in the presence of MeaF vs AmmF (b″ vs c′, Figure 3 ). Finally, MeaF 1,2-aminothiol moiety was expected to remain capable of undergoing an S → N acyl shift rearrangement to yield the desired N-alkyl macrolactam, as suggested by peptide ligation studies with other aminothiol compounds. 71 As summarized in Scheme 1B, MeaF was prepared starting from 3-nitro-benzyl bromide via alkylation with diethylacetamidomalonate and nitro group reduction by hydrogenation with Pd/C catalyst. Reductive amination of intermediate 8 with α-chloroacetaldehyde followed by substitution with triphenylmethylmercaptan resulted in the protected intermediate 10.
Deprotection with TFA followed by decarboxylation with concentrated HCl resulted in the desired amino acid MeaF in 38% isolated yield over six steps. This route could be scaled up to the gram scale (1.5 g final product) with no significant reduction in the overall yield.
AARS for Ribosomal Incorporation of MeaF. The same approach described above for AmmF was applied to identify a suitable AARS for amber stop codon suppression with MeaF. Initial screening of the panel of engineered Mj AARSs showed that both pAmF-RS and AzF-RS can recognize and incorporate MeaF into the reporter YFP protein ( Figure 2B ). At the same time, O2beY-RS emerged as the most promising enzyme for this purpose based on the approximately 20% higher fluorescent signal in the assay ( Figure 2B ). This synthetase, which carries a Ala32Gly mutation in the OpgY-RS background, was engineered by our group to accommodate tyrosine derivatives containing larger alkyl substituents at the para position. 50 Considering the much lower incorporation of MeaF obtained with OpgY-RS, this substitution is clearly beneficial also toward recognition of meta-substituted aromatic UAAs such as MeaF. Comparison of the expression yield of this protein (23 mg/L culture) with that of wild-type YFP (45 mg/ L culture) indicated a suppression efficiency as high as 52%, which is an about 16% higher efficiency than that achieved with AmmF and AzF-RS ( Figure 2C ).
In Vivo Cyclization of MeaF-Containing Precursor Proteins. To compare side-by-side the performance of MeaF vs AmmF toward promoting peptide macrocyclization in vivo, the same six constructs with a 4-mer to 12-mer target sequence (entries 1−6, Table 1) were expressed in E. coli in the presence of MeaF and the O2beY-RS-based suppressor system. Notably, SDS-PAGE analysis of these proteins revealed a significantly larger degree of intein cleavage (75−85%, Figure 5 ) as compared to that of the related AmmF-containing counterparts (20−25%) under identical expression conditions. Since the two sets of constructs differ only by the side chain aminothiol functionality in the installed UAA, these results strongly suggested that the ribosomally incorporated MeaF had remained available for nucleophilic attack on the intein thioester.
To examine the outcome of these in vivo reactions, the cleaved N-terminal fragments were isolated from the cell lysates using chitin-coated resin beads. To our delight, MALDI-TOF MS analysis of these samples revealed the occurrence of a macrocyclic product (cyc, Figure 6 ), corresponding to either the thiolactone or the isobaric lactam (species b″ and c″, respectively, in Figure 3B ), as the only or largely predominant product for the constructs with 6−12 amino acid-long target sequences. In contrast, the 4-mer and 5-mer constructs showed only MS signals consistent with the acyclic, hydrolyzed product ( Figure S5 ). Although this species could arise from hydrolysis of the full-length intein-containing precursor protein directly, the higher degree of intein cleavage observed with the MeaFcontaining vs AmmF-containing constructs ( Figure 5 ) suggests that it more likely derives from hydrolysis of the thiolactone intermediate formed after MeaF-mediated transthioesterification. Importantly, no adducts were observed for any of the constructs, indicating that the side chain functionality of MeaF did not react with pyruvate or other intracellular metabolites.
To assess the occurrence and extent of S → N acyl shift rearrangement in the 6-mer to 12-mer macrocyclic products, the corresponding cell lysate samples were first treated with iodoacetamide under alkaline conditions (pH 8) prior to chitinaffinity purification. Through this procedure, the macrolactam is converted to its corresponding S-carboxyamidomethyl adduct (m, Figure S6 ), whereas the thiolactone is hydrolyzed and 
Articles alkylated, thus appearing as the S-alkylated adduct of the linear acyclic peptide (a). These experiments showed that the 6-mer-, 10-mer-, and 12-mer-based macrocycles were present exclusively or mostly (∼90% for 12-mer) in the thiolactone form. As an exception, the 8-mer-based macrocycle was found to have undergone partial rearrangement, being present in about 40% as the desired lactam product, with the remaining 60% as thiolactone as estimated based on the intensity of the corresponding MS signals ( Figure S6C ) and assuming the two species share similar ionization properties. Collectively, these results demonstrated the ability of MeaF to efficiently mediate the first step (i.e., intramolecular transthioesterification) of the envisioned macrocyclization process within 12 h. The partial rearrangement of the 8-mer-based construct also suggested that the second step (S,N acyl shift) is comparatively much slower. This finding is consistent with the slow kinetics of the S,N acyl transfer observed for 1,2-aminothiol moieties containing secondary amines in the context of peptide ligation studies. 71 Given the remarkable stability in vivo of the thiolactone intermediate for the 6-mer to 12-mer constructs, we reasoned that longer culture times could result in the intracellular formation of the desired macrolactam product. Accordingly, cell cultures were grown for 24 h prior to isolation and analysis of the spliced products using the procedure described above. Gratifyingly, these experiments showed a dramatic increase in the S,N acyl transfer rearrangement for all the constructs. Indeed, the 6-mer-based macrocycle was found to consist for the most part of the desired lactam product (∼60%, Figure 6A ). Even better results were achieved with the 8-mer-, 10-mer-, and 12mer-based macrocycles, which were isolated exclusively in the lactam form ( Figure 6C −E). These results were corroborated by parallel tests in which the peptides were isolated via chitin affinity immediately after cell lysis under alkaline conditions (pH 8.0). Under these conditions, MS analysis revealed a macrocycle/hydrolyzed product ratio (corresponding to the lactam/thiolactone ratio) comparable or identical to the m/a ratio obtained after incubation with iodoacetamide, further confirming the occurrence of the S,N acyl transfer step inside the cells.
An intriguing aspect emerging from these studies concerns the effect of the target peptide length on the outcome of MeaFmediation peptide cyclization in vivo. Our results indicate that 4-mer and 5-mer sequences undergo MeaF-induced transthioesterification, but the resulting thiolactones are apparently susceptible to hydrolysis before the irreversible S,N acyl transfer process can take place. In contrast, both of these steps occur efficiently in the context of longer peptide sequences (6−12 amino acids). Possibly, a higher ring strain in the thiolactone intermediate and/or slower kinetics for the subsequent ring contraction step may be at the basis of the higher susceptibility of the shorter constructs toward hydrolysis. In the future, it will be interesting to determine whether alternative aminothiol UAAs and/or alterations within the peptide sequence (e.g., at the Intein-1 site) can provide access also to these smaller rings. Another implication of the results above is that 7-mer peptide sequences should also be amenable to cyclization. To test this hypothesis, the construct corresponding to entry 8 in Table 1 was prepared and expressed. As anticipated, this construct underwent extensive cyclization in vivo (∼75−80% intein cleavage), resulting in the formation of the desired CBD-fused peptide macrocycle as the major product (∼60:40 lactam/ thiolactone ratio, Figure 6B) . Altogether, these studies demonstrated the functionality of the methodology outlined in Figure 3B to orchestrate the spontaneous, intracellular formation of side chain-to-tail peptide macrocycles in E. coli.
Generation of a Streptavidin-Binding Macrocyclic Peptide in Living Cells. To demonstrate the production of a bioactive macrocyclic peptide in living cells, an additional construct (entry 9, Table 1) was designed based on a streptavidin-binding head-to-tail cyclopeptide reported by 
Articles Benkovic and co-workers. 72 In this case, the precursor protein consists of a short N-terminal tail (Met-Gly) followed by MeaF and a 11-mer peptide sequence encompassing a histidine− proline−glutamine (HPQ) motif known to interact with streptavidin. 73, 74 After expression of this construct in E. coli, cell lysates were passed over streptavidin-coated beads to isolate any streptavidin-bound material. Remarkably, analysis of the eluate revealed the presence of the desired macrocyclic peptide (cyclo(Strep1)) as the only product, as shown in the MS spectrum in Figure 7A . The lack of detectable amounts of the acyclic byproduct, which would be also captured by this procedure as determined via control experiments, indicated that MeaF-mediated cyclization had occurred with high efficiency, that is, outcompeting hydrolysis of the full-length construct and/or of the thiolactone intermediate. Furthermore, the precursor protein was determined to have undergone >75% cleavage ( Figure 7C ), a value comparable to that observed for target sequences of comparable length in the CBD-fused format. On the basis of the expression level of the isolated GyrA protein and extent of in vivo cyclization, the yield of the Strep1-derived cyclopeptide was estimated to be around 0.85 mg L −1 . Isolation of Improved Streptavidin-Binding Peptide from Macrocyclic Peptide Library. To begin to explore the potential utility of this methodology toward the discovery of macrocyclic peptides with novel or improved function, cyclo(Strep1) was subjected to mutagenesis in search for cyclopeptide variants with enhanced affinity toward streptavidin. To this end, we availed insights from the available crystal structure of streptavidin bound to a HPQ-containing peptide isolated by phage display. 73 Inspection of this complex revealed that, whereas the key HPQ motif inserts into the biotin binding site of streptavidin, the amino acid residues flanking this region also lie within short distance from the protein surface (<6 Å, Figure S7 ). In addition, these residues are likely to influence the β-turn conformation of the HPQ sequence, thereby affecting the affinity of the peptide ligand for the protein. Accordingly, a library of cyclic peptides was generated by randomizing the positions flanking the HPQ tripeptide in the Strep1 target sequence (V18, F22) using the degenerate codon NDC (12 codons/12 amino acids). In the corresponding precursor proteins, a FLAG peptide (sequence: DYKDDDDK) was placed upstream of the UAA and the semirandomized target sequence in order to obtain macrocyclic peptides with an Nterminal affinity tag useful for detection purposes. As a reference, a construct encoding for a FLAG-tagged version of cyclo(Strep1) was also prepared (entry 10, Table 1) .
To screen the library, an ELISA-like assay was implemented and validated using a synthetic biotinylated FLAG peptide. As schematically illustrated in Figure 8A , this assay relies on capturing the streptavidin-binding peptide on a streptavidincoated plate, followed by colorimetric detection and quantification of the amount of bound peptide by means of an anti-FLAG antibody−horseradish peroxidase (HRP) conjugate. After expression and cell lysis in a 96-well plate format, 480 recombinants from the Flag-Strep1(V18NDC/F22NDC) library were screened using this assay. This experiment led to the identification of 10 variants displaying a significantly enhanced response (>1.5-fold) as compared to that of the reference Flag-cyclo(Strep1) peptide ( Figure 8B ). Rescreening of these hits yielded two most promising variants, Flag-Strep2 and Flag-Strep3, which exhibited >2-fold higher signal in the immunoassay over that of the parent cyclic peptide ( Figure S8 ). Upon sequencing, Flag-Strep2 was found to carry a single mutation (F22S), whereas both of the HRP flanking positions were mutated in Flag-Strep3 (V18Y, F22D) (entries 11 and 12, Table 1 ). Interestingly, many of the other improved variants contain a Tyr or Phe residue in position 18 (4/10) and a polar residue (H, D, S, R) in position 22 (6/10), thus defining a consensus for these sites. Efficient production in vitro of the two best cyclic peptides, Flag-cyclo(Strep2) and Flag-cyclo(Strep3), confirmed that both sequences undergo MeaF-mediated cyclization, leading to the expected macrocycles as the only product ( Figure S9 ). These cyclic peptides, along with the parent cyclic peptide Flag-cyclo(Strep1), were then tested in the assay to measure their relative affinity for streptavidin ( Figure  8C ). From the resulting dose−response curve, the parent cyclic peptide was found to bind streptavidin with an equilibrium dissociation constant (K D ) of 7.7 μM. Importantly, both of the evolved macrocyclic peptides showed significantly (2-to 7-fold) improved affinity for this protein, with measured K D values of 4.2 μM (Flag-cyclo(Strep2)) and 1.1 μM (Flag-cyclo(Strep3)). Altogether, these studies provides a proof-of-principle demonstration of the utility of the present methodology in aiding the discovery of macrocyclic binders against a target protein of interest.
Conclusions. In summary, we have developed a novel and versatile methodology useful for generating peptide macrocycles from ribosomally produced polypeptides in vitro and in vivo. This approach leverages the ability of two genetically encodable aminothiol amino acids, AmmF and MeaF, to induce a side chain → C-end peptide cyclization via an intein-mediated intramolecular transthioesterification followed by ring contraction through an S,N acyl transfer rearrangement. Whereas the AmmF-based strategy ( Figure 3A) provides a means to generate macrocyclic peptides in vitro in a pH-controlled manner, the MeaF-based strategy ( Figure 3B ) offers the opportunity to achieve the spontaneous cyclization of peptide sequences of variable length (6-mer to 12-mer) and composition directly in living bacterial cells. As such, it 
Articles provides a new approach, complementary in scope to those previously reported, 49, 50 to direct the biosynthesis of cyclic peptides of completely arbitrary sequence. Compared to SICLOPPS, for example, the present method offers the versatility to access the desired peptide macrocycle in a broader range of molecular arrangements (i.e., cyclic, lariat, or Cterminally fused to a carrier protein) according to the nature of the N-terminal tail. In this study, this structural feature was leveraged to couple in-cell library generation with a highthroughput in vitro assay to achieve the affinity maturation of a streptavidin-targeting cyclic peptide. Beyond that, we expect this methodology to make possible the screening of genetically encoded cyclopeptide libraries in a wide range of other formats, which include not only intracellular selection [42] [43] [44] 48 or reporter systems 45 but also two-hybrid 75 or surface display 76 systems. Whereas the molecular size of the macrocycles currently accessible with this method (i.e., 900−1600 Da) seems to be appropriate for targeting extended biomolecular interfaces characterizing protein−protein interactions, 28−31,77 future studies will explore whether this strategy can be further evolved to provide access to smaller peptide ring structures.
■ METHODS
Cloning and Plasmid Construction. Genes encoding for the precursor proteins were placed under an ITPG-inducible T7 promoter in pET22 vectors (Novagen). Construction of the plasmids for expression of constructs CBD-4T through CBD-12T was described previously. 52 Construct 9 of Table 1 was prepared following an identical procedure. Construct 10 of Table 1 was prepared by stepwise assembly PCR using FLAG-HPQ-GyrA_for1/3, FLAG-HPQ-GyrA_-for2/3, and FLAG-HPQ-GyrA_for3/3 (Table S1 ) as forward primers, T7_Term_long_rev as reverse primer, and pET22b_CBD-12T as template. The PCR product (0.68 Kbp) was cloned into the NdeI/ XhoI cassette of pET22b(+) vector. The FLAG-Strep1-derived library was prepared through randomization of positions V18 and F22 in pET22b_FLAG-Strep1 with NDC degenete codons (= 12 codons encoding C, D, F, G, H, I, L, N, R, S, V, and Y). The corresponding plasmid library was prepared by overlap extension PCR using primers HPQ_SOE(A)_for, HPQ_SOE(A)_rev, HPQ(NDC)_SOE(B)_for, and HPQ(NDC)_SOE(B)_rev for fragment generation and then primers HPQ_SOE(A)_for and T7m _Term_long_rev for amplification of the final gene (1.35 kb), which was then cloned into the XbaI/ XhoI cassette of pET22b(+) vector. The library was transformed into E. coli DH5α cells, and a plasmid stock was generated by pooling >1000 cfu.
Synthesis of AmmF and MeaF. Detailed synthetic procedures and characterization data for AmmF and MeaF are provided as Supporting Information.
Fluorescence-Based Assay. E. coli BL21(DE3) cells were cotransformed with a pET22_YFP(stop) plasmid 50 encoding MetGly-(amber stop)YFP-His 6 and a pEVOL plasmid encoding the appropriate aminoacyl-tRNA synthetase. Cells were then grown in LB media containing ampicillin (50 mg L −1 ) and chloramphenicol (26 mg L −1 ) at 37°C overnight. The overnight cultures were used to inoculate 96-deep well plates containing minimal M9 media. At an OD 600 of 0.6, cell cultures were induced by adding arabinose (0.06%), IPTG (0.2 mM), and either AmmF or MeaF at a final concentration of 2 mM. After overnight growth at 27°C, the cell cultures were diluted (1:1) with phosphate buffer (50 mM, 150 mM NaCl, pH 7.5), and fluorescence intensity (λ ex = 514 nm; λ em = 527 nm) was determined using a Tecan Infinite 1000 plate reader. Cell cultures containing no unnatural amino acid were included as controls. Each sample was measured in triplicate.
Protein Expression and Purification. Proteins were expressed in E. coli BL21(DE3) cells cotransformed with the plasmid encoding the biosynthetic precursor and pEVOL_AzF or pEVOL_O2beY vectors. After overnight growth, cells were used to inoculate M9 medium (0.4 L) supplemented with ampicillin (50 mg L −1 ), chloramphenicol (34 mg L −1 ), and 1% glycerol. At an OD 600 of 0.6, protein expression was induced by adding L-arabinose (0.05%), IPTG (0.25 mM), and AmmF or MeaF (2 mM). Cultures were grown for an additional 12−24 h at 27°C and harvested by centrifugation at 3400g. Frozen cells were resuspended in Tris buffer (50 mM; pH 7.4) containing 300 mM NaCl and 20 mM imidazole and lysed by sonication. Protein purification by Ni-NTA affinity chromatography was carried out 
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Articles using a Tris buffer (50 mM, pH 7.4, NaCl 150 mM) containing 50 and 300 mM imidazole for protein loading and elution, respectively. Protein samples were concentrated in potassium phosphate buffer (50 mM, NaCl 150 mM, pH 7.5) and stored at −80°C.
In Vitro Macrocyclization Reactions. Reactions were carried out incubating the AmmF-containing precursor protein (50 μM) in potassium phosphate buffer (50 mM, NaCl 150 mM, pH 5.0) in the presence of TCEP (10 mM). For the thiol-catalyzed reactions, 10 mM MESNA was also added. After 1.5 h, the pH of the solution was adjusted to 5.0. Intein cleavage was monitored and quantified by SDS-PAGE, and densitometry analysis of the gel bands using ImageJ software. The low MW products (8−10 kDa) of the reactions were analyzed by MALDI-TOF using a Bruker Autoflex II mass spectrometer.
In Vivo Macrocyclization Reactions. The AmmF-containing precursor proteins were expressed in E. coli BL21(DE3) cells (50 mL culture) as described above. After 12 and 24 h of induction, cells were harvested by centrifugation (3400g), resuspended in 800 μL of potassium phosphate buffer (50 mM, NaCl 150 mM) at either pH 5.0 or 8.0, and lysed via sonication. The samples at pH 5.0 were used for detection of the thioester intermediate, and they were processed immediately. The samples at pH 8.0 were incubated with iodoacetamide (50 mM) for 3 h at RT prior to further processing. For protein isolation, the cell lysate samples were clarified by centrifugation (20 100g ) and passed over chitin-coated beads (New England Biolabs); the beads were washed with lysis buffer, and the chitin-bound proteins were eluted with 70% acetonitrile in water (1 mL) followed by MALDI-TOF MS analysis.
Isolation of Streptavidin-Binding Peptide. The Strep1(MeaF) protein construct was expressed in E. coli BL21(DE3) cells (50 mL culture) for 24 h at 27°C as described above. After harvesting, cells were resuspended in 800 μL of potassium phosphate buffer (50 mM, NaCl 150 mM, 7.5), lysed via sonication, and centrifuged at 20 100g. The clarified cell lysate was passed over streptavidin beads (Pierce), and the immobilized peptide was eluted with 70% acetonitrile in water and analyzed by MALDI-TOF MS.
Library Screening. Recombinants from the FLAG-Strep1-(V18NDC/F22NDC) library were expressed in E. coli BL21(DE3) cells in 96 deep well plates (1 mL culture) for 24 h at 27°C. After harvesting, cells were resuspended in 400 μL of TBS (Tris 50 mM, NaCl 150 mM, 7.4) and incubated for 1 h at 37°C in the presence of lysosyme, DNase, and MgCl 2 to lyse the cells, followed by centrifugation at 3400g. The clarified cell lysate (200 μL) was transferred to NeutrAvidin coated 96-well plates (Pierce) and incubated for 2 h at RT. The plates were washed three times with 200 μL of TBS + 0.5% Tween 20. Next, a solution of anti-FLAGantibody−HRP conjugate (100 μL, 1:2500 dilution) was added to each well and incubated for 1 h. The plates were washed three times with 200 μL of TBS + 0.5% Tween 20. 100 μL of SigmaFast OPD solution was added to each well, and the absorbance at 450 nm was measured after 20 min. The signals were normalized to the signal corresponding to the cells containing the FLAG-Strep1 cyclic peptide. The 10 most active variants (>1.5 rel. act.) were re-expressed and screened again in triplicate using the same procedure ( Figure S8 ).
K D Determination for Streptavidin Binding. The cyclic peptides Flag-cyclo(Strep1), Flag-cyclo(Strep2), and Flag-cyclo(Strep3) were obtained via cyclization of the corresponding full-length precursor proteins in TBS in the presence of TCEP (20 mM) and thiophenol (10 mM). The full-length precursor proteins were obtained via expression in E. coli BL21(DE3) cells for 7 h at 22°C followed by Ni-affinity purification as described above. In each case, the macrocyclization reaction proceeded quantitatively, yielding the cyclic peptide as the only product, as determined by SDS-PAGE and MS ( Figure S9) . A solution of each of the macrocyclic peptide (50 μL) was added to NeutrAvidin-coated plates at varying concentrations (0.156− 20 μM) and assayed in duplicate as described above. K D values were calculated with SigmaPlot via fitting of the dose−response curves using a 1:1 binding model.
Synthetic procedures, additional MS spectra, sequences of oligonucleotide primers, crystal structure of streptavidin in complex with a disulfide bridged peptide, SDS-PAGE gel, and results from rescreening the 10 most active variants isolated from primary screening of the Flag-Strep1(V18NDC/ F22NDC) library. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acschembio.5b00119.
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Articles S1 C NMR spectra were recorded on Bruker Avance spectrometers by using solvent peaks as reference. LC-MS analyses were performed on a Thermo Scientific LTQ Velos ESI/ion-trap mass spectrometer coupled to an Accela U-HPLC. MALDI-TOF spectra were acquired on a Bruker Autoflex III MALDI-TOF spectrometer by using a stainless steel MALDI plate and sinapinic acid as matrix.
SYNTHETIC PROCEDURES
Scheme S1: Synthesis of AmmF 
Synthesis of 2-amino-3-(3-amino-4-(mercaptomethyl)phenyl)propanoic acid (AmmF):
Compound 5 (5.4 g, 7.6 mmol, 1 eq) was added to a dry, argon-filled 250mL round-bottom flask and dissolved in 70 mL anhydrous dichloromethane. To the solution triisopropylsilane (3.88 mL, 19 mmol, 2.5 eq) was added and the reaction mixture was cooled in a ice bath. Trifloroacetic acid (18mL) was slowly added via a syringe and the reaction was left stirring under argon at 0ºC for 30 minutes. The reaction was then warmed to room temperature and volatiles were removed under reduced pressure. To this product was added 30 mL 8 M hydrochloric acid in dioxane and the reaction mixture was brought to reflux via heating mantle and allowed to stir under argon for 9 hours. Upon completion, the reaction was dried under reduced pressure to yield a brown solid, which was washed exaustively with cold hexanes to remove triphenylmethane and triisopropylsilane, yielding the dihydrochloride salt of AmmF (2.27 g , 100% 
Synthesis of diethyl 2-acetamido-2-(3-aminobenzyl)malonate (8):
A dry 500 mL flask was purged with argon and compound 7 (5 g , 14.2 mmol, 1 eq) was added. To this, 1 g Pd/C was added and the flask was capped with a septa. 115 mL degassed methanol was added via syringe while purging with argon. The reaction mixture was sparged with argon for 10min clearing the needle with methanol as needed. Once purged, the reaction was sparged with H2, again clearing the needle as needed. Reaction continued under H2 for 3 h at r.t. The flask was sparged with S7 argon to clear out the residual hydrogen gas, and the flask was washed with ethyl acetate and filtered over celite. Deionized H2O was used to quench Pd/C and the solvent was removed by rotary evaporation to yield a off-white solid (4.45 g, 97% 
Synthesis of diethyl 2-acetamido-2-(3-((2-chloroethyl)amino)benzyl)malonate (9):
Compound 8 (4.5 g, 14 mmol, 1eq) was added to a round bottom flask and dissolved in 90 mL ethanol. NaCNBH3 ( 0.97 g, 15.4 mmol, 1.1 eq) was added and the mixture was sonicated to aid solubility. Chloroacetaldehyde (2.7 mL, 15.4 mmol, 1.1 eq) was added followed by glacial acetic acid (0.81 mL, 14 mmol, 1 eq). The reaction was run at r.t. under argon for 4 h then the solvent was removed by rotary evaporation. The crude product was re-suspended in DCM and washed with H2O, then with sat. NaHCO3 and then with brine. The resulting organic layer was dried over MgSO4 and the solvent was removed by rotary evaporation. The oil was purified by flash chromatography on silica gel using a solvent gradient of 8:1 to 7:3 hexanes:ethyl acetate to yield compound 9 as a yellow oil (3.46 g, 9 mmol, 64.2% yield). 
Synthesis of diethyl 2-acetamido-2-(3-((2-(tritylthio)ethyl)amino)benzyl)malonate (10):
Compound 9 (3.46 g, 9 mmol, 1 eq) was dissolved in 85 mL anhydrous DMF. To this was added triphenyl methylmercaptan (2.73 g, 9.9 mmol, 1.1 eq) followed by potassium carbonate (1.5 g, Synthesis of 2-amino-3-(3-((2-mercaptoethyl)amino)phenyl)propanoic acid (MeaF):
Compound 5 (3.38 g, 5.4 mmol, 1 eq) was dissolved in 12 mL anhydrous DCM and the reaction mixture was purged with argon and cooled in a ice bath. The solution was added with triisopropylsilane (1.23 mL, 6.1 mmol, 1.1eq) and then with 8 mL TFA dropwise via a syringe. 
